Effect of combination treatment with GLP-1 receptor agonists and SGLT-2 inhibitors on incidence of cardiovascular and serious renal events Post date 25 April 2024 ← Autism and ADHD place “unprecedented” demand on NHS → Consultants in England accept improved pay offer